Innovation at work
The Therapeutics Discovery team is leveraging its unique bench at the bedside approach to create the next generation of cancer medicines and improve the lives of our patients. Driven by unmet patient needs, Therapeutics Discovery works closely with leading clinical experts to advance multiple new therapies from discovery to early-stage clinical trials, all under one roof. Our strategic partners enable us to bring these innovative medicines to our patients quickly, safely and effectively.
Therapeutics Discovery Pipeline
-
GSK-3174998
Novel immune-stimulating antibody targeting OX40 in Phase I clinical trials for patients with solid tumors
-
IACS-10759
Small-molecule oxidative phosphorylation inhibitor in Phase I clinical trials for patients with AML and solid tumors
-
IPN-60090
Small-molecule metabolism inhibitor targeting glutaminase in Phase I clinical trials for patients with solid tumors
-
8F4
First-in-class TCR-like antibody targeting PR1 on leukemia cells, in Phase I clinical trials for patients with MDS & AML
-
MAG-8287
Neuroprotective therapy designed for patients with chemotherapy-induced peripheral neuropathy and Alzheimer’s disease
-
IACS-15509
Small-molecule inhibitor of SHP2 oncogene developed for patients with genetically-driven and treatment-resistant cancers
-
IACS-30380
Small-molecule inhibitor of DNA-damage regulator ATR to be evaluated in patients with a variety of cancer types
-
IACS-8876
Small-molecule PRMT1 inhibitor being developed as a therapeutic option for cancers marked by PRMT1 overexpression
Strategic Alliances
By aligning with leading pharmaceutical and biotechnology companies, we are able to combine the unique infrastructure and drug development capabilities of Therapeutics Discovery with the novel therapeutics and expertise of our partners to accelerate new therapies to benefit patients.
-
Artios
In-licensing agreement by Artios of small-molecule ATR inhibitor program developed by MD Anderson and ShangPharma
-
BOEHRINGER INGELHEIM
Multi-year collaboration with TRACTION to advance Boehringer Ingelheim’s pipeline of novel medicines
-
Ionis
Partnership combining Ionis’ antisense technology with MD Anderson expertise to develop new cancer therapies
-
IPSEN
Research collaboration with IACS to conduct pre-clinical studies exploring new potential drug candidates
-
TAIHO ONCOLOGY
Partnership to conduct preclinical development and clinical evaluation of novel medicines for treating brain metastases
-
VESCOR
New company launched with IACS and Deerfield Management to discover new therapies that target autophagy to treat cancer